Patient Guide: Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 9 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05372718
Status: 🟢 Enrolling Now
Condition: Ischemia
Phase: PHASE3

Where You Can Participate

This study is available at 9 locations across the country.

Top locations include:
  • • Kursk, Kursl Region
  • • Sergiyev Posad, Moscow Region
  • • Kazan, Republic Of Tatarstan
  • • And 6 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial - Join Clinical Trial NCTNCT05372718

How to Join This Clinical Trial - NCTNCT05372718

Learn how to participate in this PHASE3 trial studying an investigational therapy for Ischemia. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Ischemia. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Ischemia
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05372718 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 9 locations. Find a study site near you:

Clinical Research Site

Kursk, Kursl Region 305035 - Russian Federation

Status: RECRUITING

Clinical Research Site

Sergiyev Posad, Moscow Region 141301 - Russian Federation

Status: RECRUITING

Clinical Research Site

Kazan, Republic Of Tatarstan 420012 - Russian Federation

Status: RECRUITING

Clinical Research Site

Moscow, 115446 - Russian Federation

Status: RECRUITING

Clinical Research Site

Moscow, 123182 - Russian Federation

Status: WITHDRAWN

Clinical Research Site

Moscow, 125284 - Russian Federation

Status: RECRUITING

Clinical Research Site

Rostov-on-Don, 344022 - Russian Federation

Status: WITHDRAWN

Clinical Research Site

Tver, 170036 - Russian Federation

Status: WITHDRAWN

Clinical Research Site

Volgograd, 400138 - Russian Federation

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Ischemia:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships